Black Diamond Therapeutics announces positive Phase 2 results for Silevertinib in frontline NSCLC patients with EGFR non-classical mutations
[출처/시간] Briefing.com - 5:15 PM ET, 05/21/2026 CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer patients with epidermal growth factor receptor non-classi
[출처/시간] Briefing.com - 5:15 PM ET, 05/21/2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer patients with epidermal growth factor receptor non-classical mutations. These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT.Click here for full release.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
